Rugocrixan

N/A

Report date: 2025/06/26 16:54:56
NME

Base Information

Drug NameRugocrixan
Drug Alias NameAZD-8797KAND-567KAN-0440567
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X3-C motif chemokine receptor 1 antagonists
TargetsC-X3-C motif chemokine receptor 1
Therapy Area/IndicationsCancer PainAutoimmune DiseasesMultiple Sclerosis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenNorwayDenmark +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesKancera ABAstrazeneca Pharmaceutical Co LtdRecardio Inc
Inactive CompaniesN/A
Active IndicationsCancer PainAutoimmune DiseasesMultiple Sclerosis +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A